Replicating live attenuated OPV is no longer available in the UK, having been replaced in 2004 with the trivalent (serotypes 1-3) enhanced inactivated poliovirus vaccine (IPV) in all routine vaccine schedules. The vaccine is given to adults in combination with tetanus and diphtheria toxoid (Td/IPV). The vaccine is given by parenteral administration. IPV is highly immunogenic. Antibodies to all three poliovirus serotypes develop in >90% of healthy recipients after 2 doses and in >99% after 3 doses. The duration of immunity conferred by IPV is not known. A total of five vaccine doses at the appropriate intervals (as per the UK childhood vaccination schedule) are considered to give lasting immunity, with reinforcing doses recommended every 10 years for those at risk. The vaccine is well tolerated. Injection site reactions are common but usually self-limited and may occur more frequently following subsequent doses. Fever and other systemic reactions are uncommon. Severe systemic reactions are rare.